Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSK-IM02 in Advanced Solid Tumors With Malignant Pleural or Peritoneal Effusions
NCT07615894Phase 1Not yet recruiting
- Sponsor
- WestVac Biopharma
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WSK-IM02 in solid tumor, malignant pleural effusion (MPE) and malignant ascites, sponsored by WestVac Biopharma. Primary endpoint: Adverse Events at 28 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
WSK-IM02
03
Conditions
solid tumormalignant pleural effusion (MPE)malignant ascites
Beyond the preview
Go deeper on NCT07615894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615894.